DK0532595T3 - Farmakologisk anvendelse af visse cystinderivater - Google Patents

Farmakologisk anvendelse af visse cystinderivater

Info

Publication number
DK0532595T3
DK0532595T3 DK91910813.4T DK91910813T DK0532595T3 DK 0532595 T3 DK0532595 T3 DK 0532595T3 DK 91910813 T DK91910813 T DK 91910813T DK 0532595 T3 DK0532595 T3 DK 0532595T3
Authority
DK
Denmark
Prior art keywords
cysteine derivatives
pharmacological use
certain cysteine
certain
pharmacological
Prior art date
Application number
DK91910813.4T
Other languages
English (en)
Inventor
Carl-Magnus Alexande Andersson
Sten Hakan Axel Bergstrand
Anders Rudolf Hallberg
Bengt Olof Saernstrand
Per Anders Sigvard Tunek
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002067A external-priority patent/SE9002067D0/xx
Priority claimed from SE9002275A external-priority patent/SE9002275D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Application granted granted Critical
Publication of DK0532595T3 publication Critical patent/DK0532595T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
DK91910813.4T 1990-06-08 1991-06-03 Farmakologisk anvendelse af visse cystinderivater DK0532595T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9002067A SE9002067D0 (sv) 1990-06-08 1990-06-08 The pharmacological use of certain cystine derivatives
SE9002275A SE9002275D0 (sv) 1990-06-28 1990-06-28 Novel 3,3'-dithiobis(propionic acids)
PCT/SE1991/000388 WO1991018594A1 (en) 1990-06-08 1991-06-03 The pharmacological use of certain cystine derivatives

Publications (1)

Publication Number Publication Date
DK0532595T3 true DK0532595T3 (da) 1997-04-07

Family

ID=26660796

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910813.4T DK0532595T3 (da) 1990-06-08 1991-06-03 Farmakologisk anvendelse af visse cystinderivater

Country Status (20)

Country Link
US (2) US5441976A (da)
EP (1) EP0532595B1 (da)
JP (1) JP3204320B2 (da)
KR (1) KR100236253B1 (da)
AT (1) ATE144705T1 (da)
AU (1) AU652946B2 (da)
CA (1) CA2083274C (da)
DE (1) DE69122961T2 (da)
DK (1) DK0532595T3 (da)
HK (1) HK62597A (da)
HU (1) HU215920B (da)
IE (1) IE80754B1 (da)
IL (1) IL98310A (da)
LV (2) LV10186B (da)
NO (1) NO924723D0 (da)
NZ (1) NZ247658A (da)
PT (1) PT97905B (da)
RU (1) RU2119793C1 (da)
SG (1) SG49736A1 (da)
WO (1) WO1991018594A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018994D0 (en) * 1990-08-31 1990-10-17 Secr Defence Toxic agent protective compounds
US5889050A (en) * 1991-06-21 1999-03-30 Astra Aktiebolag 3,3'-dithiobis (propionic acids) and esters thereof
SE9103572D0 (sv) * 1991-11-29 1991-11-29 Astra Ab Organic salts of n,n'-diacetyl cystine
JP2947044B2 (ja) * 1993-01-27 1999-09-13 味の素株式会社 免疫不全症候群治療の補助療法剤
DE4329857C2 (de) * 1993-09-03 1995-08-24 Deutsches Krebsforsch Verbindung zur Stärkung des Immunsystems und von Immunreaktionen
SE9500897D0 (sv) * 1995-03-14 1995-03-14 Astra Ab The pharmacological use of certain cystine derivatives
SE9501067D0 (sv) * 1995-03-24 1995-03-24 Astra Ab New peptides
SE9602262D0 (sv) * 1996-06-06 1996-06-06 Astra Ab New use of derivatives of cystine
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US6703031B1 (en) 1998-10-09 2004-03-09 Ajinomoto Co., Inc. Cysteine derivatives
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
SE9900438D0 (sv) * 1999-02-10 1999-02-10 Astra Ab The pharmacological use of certian cystine derivatives
JP3988014B2 (ja) * 2000-02-02 2007-10-10 味の素株式会社 ウイルス感染症予防剤
EP3269360A1 (en) 2000-11-30 2018-01-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
SE518784C2 (sv) * 2000-12-27 2002-11-19 Nactilus Ab "N-Acetyl-L-cystein med kompositioner för behandling av neoplasier"
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
DE102004043055B4 (de) 2004-09-06 2009-04-02 Siemens Ag Führungsvorrichtung zur Führung eines bewegbaren Maschinenelementes einer Maschine
WO2008066603A2 (en) * 2006-10-03 2008-06-05 Galleon Pharmaceuticals, Inc. S-nitrosothiol compounds and related derivatives
CN104758281A (zh) * 2007-04-23 2015-07-08 西佳技术公司 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
JP5796881B2 (ja) * 2008-02-07 2015-10-21 マーケット ユニバーシティー 統合失調症を治療するため及び薬物渇望を低減するためのシステイン及びシスチンプロドラッグ
JP6458809B2 (ja) 2014-04-25 2019-01-30 味の素株式会社 免疫賦活剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8205M (da) * 1968-12-20 1970-09-14
US3878305A (en) * 1972-05-25 1975-04-15 Procter & Gamble Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids
US3952115A (en) * 1975-04-02 1976-04-20 The Procter & Gamble Company Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters
GB2097256B (en) * 1981-04-02 1985-05-30 Morelle Jean V Compositions containing n-butyryl alphaaminoacids
FR2503151A1 (fr) * 1981-04-02 1982-10-08 Morelle Jean Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux
US4827016A (en) * 1985-09-16 1989-05-02 Morgan Lee R Method and compounds for reducing dermal inflammations
US4708965A (en) * 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
US4724239A (en) * 1985-09-16 1988-02-09 Morgan Lee R Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine
IT1249650B (it) * 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico

Also Published As

Publication number Publication date
HU215920B (hu) 1999-03-29
EP0532595A1 (en) 1993-03-24
IE80754B1 (en) 1999-01-13
DE69122961D1 (de) 1996-12-05
LV10186B (en) 1995-08-20
IL98310A0 (en) 1992-06-21
AU8094191A (en) 1991-12-31
CA2083274A1 (en) 1991-12-09
US5780508A (en) 1998-07-14
NO924723L (no) 1992-12-07
PT97905A (pt) 1992-03-31
HK62597A (en) 1997-05-16
NO924723D0 (no) 1992-12-07
EP0532595B1 (en) 1996-10-30
IE911945A1 (en) 1991-12-18
US5441976A (en) 1995-08-15
AU652946B2 (en) 1994-09-15
RU2119793C1 (ru) 1998-10-10
SG49736A1 (en) 1998-06-15
LV11985B (en) 1998-06-20
HUT70055A (en) 1995-09-28
CA2083274C (en) 2002-05-28
KR100236253B1 (ko) 1999-12-15
DE69122961T2 (de) 1997-03-13
JP3204320B2 (ja) 2001-09-04
HU9203871D0 (en) 1993-03-29
WO1991018594A1 (en) 1991-12-12
PT97905B (pt) 1998-10-30
ATE144705T1 (de) 1996-11-15
LV10186A (lv) 1994-10-20
JPH05507705A (ja) 1993-11-04
LV11985A (lv) 1998-03-20
NZ247658A (en) 2000-07-28
IL98310A (en) 1996-08-04

Similar Documents

Publication Publication Date Title
DK0532595T3 (da) Farmakologisk anvendelse af visse cystinderivater
FI913248A (fi) Kontrollerat frigoerande fast farmaceutisk doseringsform.
ES2083668T5 (es) Combinaciones antiviricas que contienen analogos de nucleosido.
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
YU74292A (sh) Jedinjenja za inhibiciju hiv i srodnih virusa
FI925778A0 (fi) Farmaceutiskt aktiva bensokinazolinfoereningar
NO874955D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heteroaromatiske aminderivater.
DK0697887T3 (da) Stabile flydende gamma-interferonholdige præparater
DK561089A (da) Anvendelse af lactamimider til fremstilling af laegemidler
NO911065L (no) Fremgangsmaate for fremstilling av lipopeptidderivater.
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
ES2056955T3 (es) Formulacion oral de buspirona y sales de la misma.
FI951092A (fi) Fluoreseiinijohdannaisten stabiilit korkeakonsentroidut valmisteet
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
ES2114891T3 (es) Nuevas formulaciones farmaceuticas de 5-(2-cloro-1-hidroxietil)-4-metiltiazol.
SE9602262D0 (sv) New use of derivatives of cystine
DK34882A (da) Fremgangsmaade til fremstilling af peptidderivater
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments
NO903705D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n-disubstituerte arylcykloalkylaminer.
GR1001368B (el) Φαρμακευτικοί φορείς.
NO900812D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive laktamderivater.
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом